首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   768篇
  免费   61篇
  国内免费   8篇
耳鼻咽喉   2篇
儿科学   1篇
妇产科学   1篇
基础医学   34篇
口腔科学   2篇
临床医学   86篇
内科学   201篇
神经病学   4篇
特种医学   44篇
外科学   84篇
综合类   143篇
预防医学   37篇
眼科学   1篇
药学   79篇
中国医学   118篇
  2024年   4篇
  2023年   12篇
  2022年   42篇
  2021年   64篇
  2020年   48篇
  2019年   44篇
  2018年   34篇
  2017年   40篇
  2016年   45篇
  2015年   20篇
  2014年   68篇
  2013年   58篇
  2012年   44篇
  2011年   58篇
  2010年   36篇
  2009年   26篇
  2008年   21篇
  2007年   41篇
  2006年   25篇
  2005年   22篇
  2004年   11篇
  2003年   6篇
  2002年   6篇
  2001年   11篇
  2000年   6篇
  1999年   10篇
  1998年   2篇
  1997年   2篇
  1996年   3篇
  1995年   4篇
  1994年   2篇
  1993年   1篇
  1992年   3篇
  1991年   1篇
  1990年   2篇
  1988年   2篇
  1987年   2篇
  1986年   1篇
  1985年   1篇
  1984年   2篇
  1982年   1篇
  1980年   1篇
  1979年   1篇
  1978年   2篇
  1973年   1篇
  1971年   1篇
排序方式: 共有837条查询结果,搜索用时 7 毫秒
61.
中西医结合治疗原发性痛风临床研究   总被引:1,自引:0,他引:1  
目的探讨中西医结合治疗原发性痛风的临床疗效。方法将33例原发性痛风患者随机分为中西医结合治疗组(治疗组)与单纯西药治疗组(对照组)。对照组常规服用别嘌呤醇、秋水仙碱,必要时静滴抗生素或激素。治疗组除以上方法外还加用中医药治疗。结果治疗组总有效率为90.5%(19/21)与对照组总效率58.3%(7/12)比较,经统计学处理有差异(P<0.05)。前者疼痛缓解时间均值为36.56小时与后者疼痛时间均值为42.52小时,统计学处理有显著差异(P<0.001)。治疗组3年内复发率为33.3%(7/21),对照组复发率为83.3%(10/12),统计学处理有非常显著差异(P<0.005)。结论本组研究为以后中西医结合治疗痛风提供了方法和经验。  相似文献   
62.
痛风性关节炎的X线诊断   总被引:4,自引:0,他引:4  
目的总结38例痛风性关节炎的X线表现,探讨痛风性关节炎的X线诊断和鉴别诊断,以提高对本病的认识和诊断准确率。方法对38例确诊为痛风性关节炎的X线表现及病理、临床表现、实验室检查并结合文献进行总结分析。结果痛风性关节炎多发生于四肢小关节,尤以第一跖趾关节为最好发。X线表现主要是软组织偏侧性肿胀,可见散在钙化影;骨质侵蚀性破坏呈穿凿状、蜂窝状缺损,边缘锐利、硬化;关节间隙狭窄,关节面不规整,可发生纤维强直,甚至关节畸形,也可发生半脱位或脱位,可伴有骨质增生,邻近骨质疏松。结论痛风性关节炎的X线表现呈多样化,易与其他单发或多发骨关节病混淆,必须认真分析其X线征象并结合临床表现及实验室检查才能作出正确诊断。  相似文献   
63.
目的:了解风湿科门诊的常见病种、发病危险因素和诊治状况等。方法:对2005年7月18日~7月27日就诊于中山医院风湿科门诊的98例患者以问卷的形式进行横断面调查,结果进行统计分析。结果:就诊患者以中年者居多,职业多为工人,痛风、类风湿关节炎(类风关)比例在一半以上。患者多在就诊后2年应用改变病情药物(DMARDs)。痛风患者以工人、科研工作者、经商者居多。类风关患者平均在关节痛出现3年后服用DMARDs,有81.48%的患者服用该类药物,其中绝大多数患者服用甲氨蝶呤(MTX),其次为MTX与青霉胺或与柳氮磺胺吡啶联合用药。类风关患者HAQ分值最高。结论:风湿疾病的疾病谱较前有所改变,痛风成为最常见病种。DMARDs的应用率较广,但未被早期应用。风湿疾病中以类风关患者的生活质量为较差,痛风者相对较好。  相似文献   
64.

Objective

To describe the characteristics and management of patients with gout in France during the year 2014.

Methods

Data were obtained from a computerized observational longitudinal patient database of a representative sample of 1200 general practitioners. Patients on urate-lowering treatment and/or colchicine were described by demographics and comorbidities, quality of management indicators (serum uric acid and renal function testing) and treatment (type of urate-lowering treatment, change and dose regimen).

Results

We identified 14,400 patients (84.4% men, mean age: 67.5 years) with gout in the database. The most frequent comorbidities were hypertension (70%), dyslipidemia (51%), diabetes (24%) and obesity (23%). The proportion with uric acid and renal function testing data was 32% and 29%, respectively. In gout patients, only 39% had a serum uric acid < 6 mg/dL. Among treated gout patients, 76% were receiving allopurinol at a mean dose lower than 200 mg/d, most without any further change of dose regimen over one year.

Conclusion

These data outlined the persistence of clinical inertia in 2014 for patients with gout.  相似文献   
65.

Objectives

To validate the gout activity score (GAS) against the gout impact scale in a primary care based gout cohort.

Methods

This was a single-centre cross-sectional study. People with gout who participated in previous research at academic rheumatology, University of Nottingham, UK, and consented for participation in future studies were mailed a questionnaire in September 2015. Those returning completed questionnaires were invited to attend for a study visit at which blood was collected and musculoskeletal examination was performed. The Gout Assessment Questionnaire, which contains the gout impact scale (GIS), and short form (SF) 36v2 questionnaires were completed. The GAS3-step-c score was calculated. Spearman's correlation coefficient was calculated to examine correlation between GAS and SF-36 v2, and GIS. Statistical analyses were performed using PASW v22.

Results

One hundred and two (93% men) of the 150 participants who were mailed a questionnaire attended the study visit. Their mean (SD) age, body mass index, serum uric acid and GAS were 67.94 (9.93) years, 29.96 (4.57) kg/m2, 5.25 (1.75) mg/dl, and 2.99 (0.74) respectively. There was moderate correlation between GAS and gout concern overall, unmet gout treatment need, and gout concern during an attack components of GIS (r = 0.306 to 0.453), but no to poor correlation between GAS and summary scores and scales of SF-36 v2 (r = –0.090 to –0.251).

Conclusion

This first study to validate GAS against the GIS found moderate correlation. However, this study did not examine the predictive validity of GAS, and prospective studies are needed before GAS can be used widely.  相似文献   
66.

Objective

Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.

Methods

We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20 years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.

Results

We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13).

Conclusion

In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.  相似文献   
67.
目的 探讨海马区DTI在男性痛风合并轻度认知功能障碍(MCI)患者中的应用价值。方法 病例组纳入男性痛风患者35例,其中痛风合并MCI(gout-MCI)亚组15例,痛风合并认知功能正常(gout-CN)亚组20例,记录病例组患者最高血尿酸水平及近5年平均血尿酸水平。另选取15名健康志愿者作为正常对照组。对所有受检者行简明精神状态检查量表(MMSE)及蒙特利尔认知评估量表(MoCA)评分后,行常规颅脑MR和DTI检查,测量并记录FA、ADC值,并进行统计学分析。结果 gout-MCI亚组患者近5年平均血尿酸水平低于gout-CN组患者(P<0.05)。gout-MCI亚组患者海马FA值低于gout-CN亚组及正常对照组(P<0.05),gout-MCI亚组患者海马ADC值高于gout-CN组及正常对照组(P<0.05)。gout-CN亚组患者海马FA值、ADC值与正常对照组差异无统计学意义(P>0.05)。gout-MCI亚组患者海马FA值与MoCA评分呈正相关(P<0.05),与MMSE评分无相关性,右侧海马ADC值与MoCA评分呈负相关(P=0.04)。结论 颅脑DTI技术可早期检测痛风合并MCI患者双侧海马的损伤。  相似文献   
68.
Colchicine (COL) has been used in medicine for a long time. It is well recognized as a valid therapy in acute flares of gouty arthritis, familial Mediterranean fever (FMF), Behçet's disease, and recurring pericarditis with effusion. It has also been used to treat many inflammatory disorders prone to fibrosis, mostly with disappointing therapeutic results.The pharmacotherapeutic mechanism of action of COL in diverse diseases is not fully understood, thought it is known that the drug accumulates preferentially in neutrophils, and this effect is useful in FMF.COL shows a large interindividual bioavailability. Furthermore, interactions with drugs interfering with CYP3A4 dependent enzymes and P-glycoprotein occur and are clinically important. The dosage of COL must be reduced in patients with relevant hepatic and/or renal dysfunction. However, when appropriately used and contraindications have been excluded, oral COL is a safe treatment.  相似文献   
69.
痛风性关节炎的X线诊断   总被引:1,自引:0,他引:1  
张自新 《黑龙江医学》2010,34(2):128-129
目的分析痛风性关节炎的X线诊断。方法对我院被确诊为痛风性关节炎患者的X线片进行分析。结果痛风性关节炎的X线表现为手足小关节的骨质破坏缺损。结论痛风性关节炎的X线表现为手足小关节发病,但以第1跖趾关节常见。  相似文献   
70.
痛风颗粒抗炎降尿酸作用的实验研究   总被引:2,自引:0,他引:2  
目的:通过痛风颗粒对大鼠痛风性关节炎及痛风性高尿酸血症防治作用的实验研究,初步探究其药效学作用。方法:采用微晶型尿酸钠(monosodium urate,MSU)致大鼠踝关节肿胀、足跖肿胀模型和尿酸(uric acid,UA)诱导大鼠高尿酸血症模型,测定大鼠足肿胀率、患肢压力及步态积分、血尿酸值、白细胞计数及肾脏重量系数。结果:痛风颗粒能有效抑制大鼠踝关节、足跖肿胀以及患肢压力和步态积分,并能显著改善高尿酸血症大鼠体内尿酸水平,高剂量痛风颗粒能明显抑制白细胞增生。结论:痛风颗粒具有抑制炎症及降低血清高尿酸的作用。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号